MICROVIABLE-THERAPEUTICS
19.4.2022 11:02:07 CEST | Business Wire | Press release
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM ) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life” , said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euroAtlantic Airways Adds Second A330-300, Expanding Widebody Capacity28.10.2026 11:00:00 CET | Press release
euroAtlantic Airways (“EAA”), a Njord Partners portfolio company and a Portuguese ACMI and charter airline, has added a second Airbus A330-300 leased from Jackson Square Aviation (JSA), further expanding its widebody capacity. The second aircraft arrived in Portugal on 28 October 2026, bringing EAA’s total fleet size to eight. The first aircraft, CS-TGI, has already been inducted into EAA’s Air Operator Certificate and is operating commercial flights, including short-term ACMI and charter assignments. The second aircraft, an Airbus A330-300 which will carry the registration CS-TGJ, will now go through induction into EAA’s Air Operator Certificate, subject to the usual regulatory approvals. Both aircraft are leased from JSA and seat 290 passengers across three classes. The addition of the second aircraft strengthens EAA’s ability to serve a diversified range of customer requirements across global markets. In line with its long-term plans, EAA is well positioned for continued disciplined
Blue Matter Acquires Cognite, a Leading Healthcare Communications Agency28.10.2026 11:00:00 CET | Press release
Blue Matter, a world-class consulting firm serving the life sciences industry, today announced the acquisition of Cognite, a leading global healthcare communications agency that helps pharmaceutical and biotech companies bring science to life through an impressive range of scientific, medical, and commercial communications services. Cognite represents a significant step forward in strengthening Blue Matter’s growing range of communications capabilities. “Blue Matter is recognized as a valuable strategic resource and a thought leader when it comes to corporate, portfolio, product, and functional strategy in biopharma,” said Blue Matter CEO Ashwin Dandekar. “Over the past few years, we’ve been systematically bringing together the creative and communications capabilities that are often so crucial to bringing those strategies to life with healthcare providers, patients, payers, investors, and other stakeholders. Cognite’s array of capabilities, creativity, and team culture are a perfect fi
Financial Services Increases AI Investment Faster Than Wider Market, While Maturity Remains Level28.10.2026 09:56:00 CET | Press release
HTEC research finds 42% of financial services and insurance executives report significantly increased AI investment, compared with 28% across industries, while AI maturity remains in line with the wider market HTEC, the global AI technology and engineering leader, today released its research on AI Value realization in financial services and Insurance. Organizations in this sector are increasing AI investment more aggressively than the wider market, but the sector has yet to establish a corresponding lead in AI maturity, according to new research from HTEC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028854882/en/ HTEC, the global AI technology and engineering leader, today released its research on AI Value realization in financial services and Insurance. Organizations in this sector are increasing AI investment more aggressively than the wider market, but the sector has yet to establish a corresponding lead in AI matur
Powens Launches Connector Agentic Factory, an AI System to Build and Fix Open Finance Connectors28.10.2026 09:00:00 CET | Press release
A new chapter in Powens' ambition: Connector Agentic Factory is Powens' new AI system to build, extend and repair Open Finance connectors, a key step toward becoming the most complete and reliable Open Finance infrastructure in EuropeAlready at work: 12 new connectors delivered across Europe, and repairs completed in minutes rather than daysNo control loss: every connector the AI proposes is still reviewed and approved by Powens engineers before it goes live Powens, a leading European Open Finance infrastructure provider, today announced the launch of its Connector Agentic Factory, an internal AI system that is capable of building new Open Finance connectors and repairing existing ones. Connectors are the technical links that let banks, fintechs, and financial apps securely retrieve a customer's financial data, or make payments, from a bank or other institution. Powens maintains more than 1,800 of them across Europe, and they underpin the services that banks, fintechs, lenders, wealth
Ant International CEO: Achieving Inclusion Is Critical to Re-Globalisation, and AI Will Accelerate It by Democratising Opportunities28.10.2026 07:24:00 CET | Press release
Speaking at the United Nations Trade and Development (UNCTAD) World Investment Forum 2026 panel, “Investing in AI for an Inclusive Digital Future”, Ant International CEO Peng Yang called for a new, inclusive “re-globalisation” project that harnesses AI and digital connectivity to give small and medium-sized enterprises (SMEs) greater access to global markets and opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027567337/en/ Ant International CEO Peng Yang speaks at the United Nations Trade and Development (UNCTAD) World Investment Forum 2026 “Globalisation 1.0 mostly benefited large enterprises, and a lot of SMEs very rarely got to participate in the global economy,” said Yang. “Achieving inclusion is critical to re-globalisation, and AI will accelerate it by democratising opportunities.” 1. The limitation of Globalisation 1.0 and how AI and other innovations offer a chance to improve Yang said one of the gre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom